By Marcia Dunn

NASA is returning to sizzling Venus, our closest yet perhaps most overlooked neighbor, after decades of exploring other worlds.

The space agency's new administrator, Bill Nelson, announced two new robotic missions to the solar system's hottest planet, during his first major address to employees Wednesday.

“These two sister missions both aim to understand how Venus became an inferno-like world capable of melting lead at the surface," Nelson said.

One mission named DaVinci Plus will analyze the thick, cloudy Venusian atmosphere in an attempt to determine whether the inferno planet ever had an ocean and was possibly habitable. A small craft will plunge through the atmosphere to measure the gases.

It will be the first U.S.-led mission to the Venusian atmosphere since 1978.

The other mission, called Veritas, will seek a geologic history by mapping the rocky planet’s surface.

“It is astounding how little we know about Venus," but the new missions will give fresh views of the planet's atmosphere, made up mostly of carbon dioxide, down to the core, NASA scientist Tom Wagner said in a statement. “It will be as if we have rediscovered the planet.”

NASA’s top science official, Thomas Zurbuchen, calls it “a new decade of Venus.” Each mission — launching sometime around 2028 to 2030 — will receive $500 million for development under NASA’s Discovery program.

The missions beat out two other proposed projects, to Jupiter's moon Io and Neptune's icy moon Triton.

The U.S. and the former Soviet Union sent multiple spacecraft to Venus in the early days of space exploration. NASA's Mariner 2 performed the first successful flyby in 1962, and the Soviets' Venera 7 made the first successful landing in 1970.

In 1989, NASA used a space shuttle to send its Magellan spacecraft into orbit around Venus.

The European Space Agency put a spacecraft around Venus in 2006.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
FDA Panel Recommends Pfizer Vaccine for Kids Ages 5-11
An FDA panel has recommended the low-dose Pfizer vaccine for kids ages five to 11. The recommendation now cues up the FDA to authorize the vaccine. Next week, the CDC will consider its own authorization. Once signed off by the CDC, the Pfizer vaccine can be administered in children immediately. Dr. Christina Johns, Senior Medical Advisor at PM Pediatrics, joined Cheddar's Search for a Cure.
A Look Ahead at G20 Summit and COP26 on Addressing the Climate Crisis
World leaders will converge this weekend at the 2021 G20 Summit in Rome and the UN COP26 conference in Glasgow with the climate crisis on the agenda. Lord Adair Turner, chair of the Energy Transitions Commission, joined Cheddar to discuss what people can expect to come out of the climate-focused conferences. Turner also noted that one of the biggest hurdles for the attending nations will be coming to a uniform decision on expanding on the Paris Climate Accord goals that have become insufficient to prevent global warming by 1.5 degrees celsius.
Expanding Genetic Testing for Women Everywhere
Nicole Lambert, President at Myriad Genetics joins ChedHER to discuss how to expand access to genetic testing for all women, and how her experience as a 'pre-vivor' motivates her role in the industry.
Proptech Startup Juno Raises $20 Million
Proptech startup Juno recently raised $20 million in a Series A funding round. The company says the funds will be used to further its mission of building sustainable and affordable apartment buildings across the United States. Juno Co-Founder and CEO Jonathan Sherr joined Cheddar News' Closing Bell to discuss.
Innovation in Breast Cancer Screening
Stacey Stevens, President of iCAD, joins 'Cheddar Innovates' to discuss how 'Profound A.I. Risk' works as a short-term breast cancer risk estimation for women.
Merck to Offer Poorer Countries COVID-19 Pill Formula for Free
Pharmaceutical company Merck has announced that it will share the formula of its COVID-19 pill with poor countries free of charge. The company still intends to charge wealthier nations leaving the end cost at more than $700 per five-day treatment course.
Deal or No Deal, ISIS Threat & Memecoin Insanity
Dems race for a deal on President Biden's economic agenda ahead of his big foreign trip. What to make of the latest threat assessment in Afghanistan. Plus, the meme cryptocurrency of the moment that's now worth more than many Fortune 500 companies.
Load More